Using Passive Antibody Therapies in the Next Pandemic

Area of Science:

• Infectious Diseases
• Public Health
• Immunology

Background:

• The 21st century has seen seven human viral pandemics, with a new one emerging every 3-4 years.
• Emergent infectious diseases pose a high risk, and no specific therapeutics are available at the onset of pandemics.
• Passive antibody therapies, including convalescent plasma, monoclonal antibodies, and hyperimmune globulins, show promise if strategically planned and deployed.

Purpose of the Study:

• To highlight the urgent need for preparedness against future viral pandemics.
• To advocate for the strategic development of passive antibody therapies for pandemic response.
• To outline necessary pre-pandemic and in-pandemic actions for effective implementation.

Main Methods:

• Review of recent pandemic trends and their frequency.
• Analysis of the potential role and limitations of passive antibody therapies.
• Proposal of a multi-faceted strategy for pandemic readiness.

Main Results:

• The high frequency of pandemics underscores the need for immediate action.
• Passive antibody therapies can be rapidly available from survivors.
• Strategic planning is crucial for the effective production and deployment of these therapies.

Conclusions:

• Proactive strengthening of clinical, research, and manufacturing infrastructure is essential.
• Pre-pandemic reinforcement of blood banks, plasma fractionation, and outpatient infusion capabilities is vital.
• Streamlined regulatory processes, provider education, and national resource coordination are critical for pandemic response.